Featured Research

from universities, journals, and other organizations

Follow-up program helps detect melanoma earlier in high-risk patients

Date:
March 29, 2011
Source:
JAMA and Archives Journals
Summary:
A follow-up program for patients at high risk of developing skin cancer appears to be associated with the detection of melanomas at early stages and with good prognosis, according to a new study.

A follow-up program for patients at high risk of developing skin cancer appears to be associated with the detection of melanomas at early stages and with good prognosis, according to a report posted online that will appear in the May print issue of Archives of Dermatology, one of the JAMA/Archives journals.

Efforts to improve melanoma prognosis have focused on identifying and closely monitoring individuals at high risk, according to background information in the article. "Fair-skinned persons, persons who tan with difficulty, blond or red-haired persons and persons with blue eyes have more risk of developing melanoma than the general population," the authors write. "The presence of many pigmented lesions, including freckles and clinically typical or atypical nevi; intermittent sun exposure and severe sunburns, especially during childhood; and exposure to artificial UV-A radiation have all been associated with an increased risk of melanoma." Individuals with a personal or family history of melanoma are also at high risk.

Dermoscopy -- a noninvasive diagnostic technique in which a clinician performs a microscopic evaluation of a skin lesion -- improves the accuracy of melanoma diagnoses, the authors note. Gabriel Salerni, M.D., of Hospital Clinic of Barcelona, Institut d'Investigacions Biomιdiques August Pi I Sunyer, Barcelona, and colleagues analyzed data from 201 patients diagnosed with melanoma in one specialized unit, including 40 who were in a follow-up program for high-risk individuals and 161 who were referred for evaluation by another clinician. All melanomas diagnosed among these patients were evaluated by dermoscopy.

Most of the melanomas diagnosed in the follow-up program did not match clinical or dermoscopic features characteristic of melanoma. For example, only 12 percent fulfilled all four ABCD criteria outlined for melanoma detection -- asymmetry (A), uneven borders (B), colors (C) and differential dermoscopic structures (D). This compares with 63.6 percent of the melanomas detected among individuals referred to the institution but not in the follow-up program.

In addition, 70 percent of melanomas diagnosed in the follow-up group were in situ (had not spread beyond the initial site), compared with 27.9 percent of those in the referred group. The Breslow index -- a measure of tumor thickness -- was also lower among the melanomas diagnosed through the follow-up program. The follow-up cancers also tended to be diagnosed at earlier stages: 70 percent were diagnosed at stage zero and 30 percent at stage IA. Among the referral group, 27.9 percent were diagnosed at stage zero, 37.6 percent at stage IA, 12.7 percent at stage IB, 10.9 percent at stage II, 8.5 percent at stage III and 2.4 percent at stage IV.

"The inclusion of patients who are high risk for melanoma in follow-up programs allows the detection of melanoma in early stages, with good prognosis, even in the absence of clinical and dermoscopic features of melanoma," the authors conclude. "In the general population without specific surveillance, melanoma continues to be diagnosed at more advanced stages. Our findings suggest that current efforts in public and medical education might have no substantial effect in this group. Further strategies and educational programs may be needed to improve the early detection of these lesions. We believe that high-risk individuals, whenever proper resources are available, should be referred to melanoma centers or qualified institutions for regular follow-up."


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. Gabriel Salerni; Louise Lovatto; Cristina Carrera; Susana Puig; Josep Malvehy. Melanomas Detected in a Follow-up Program Compared With Melanomas Referred to a Melanoma Unit. Archives of Dermatology, 2011; DOI: 10.1001/archdermatol.2010.430

Cite This Page:

JAMA and Archives Journals. "Follow-up program helps detect melanoma earlier in high-risk patients." ScienceDaily. ScienceDaily, 29 March 2011. <www.sciencedaily.com/releases/2011/01/110117161446.htm>.
JAMA and Archives Journals. (2011, March 29). Follow-up program helps detect melanoma earlier in high-risk patients. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/01/110117161446.htm
JAMA and Archives Journals. "Follow-up program helps detect melanoma earlier in high-risk patients." ScienceDaily. www.sciencedaily.com/releases/2011/01/110117161446.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins